ENJAYMO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ENJAYMO (ENJAYMO).
ENJAYMO (sutimlimab-jome) is a monoclonal antibody that binds to complement component C1s and inhibits the activation of the classical complement pathway. This prevents the destruction of red blood cells, platelets, and endothelial cells by the complement system.
| Metabolism | Sutimlimab-jome is a monoclonal antibody. It is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes are involved. |
| Excretion | Renal: <1% unchanged; primarily eliminated via FcRn-mediated catabolism; no biliary/fecal excretion data |
| Half-life | 6-8 days (terminal half-life); prolonged due to FcRn binding, allowing monthly dosing |
| Protein binding | High affinity binding to C5 with negligible binding to other plasma proteins; not saturable at therapeutic concentrations |
| Volume of Distribution | 0.1-0.2 L/kg (primarily confined to intravascular space, consistent with limited tissue distribution) |
| Bioavailability | Intravenous: 100% (absolute bioavailability); not administered via other routes |
| Onset of Action | Intravenous: clinical improvement observed within 1-2 weeks; maximal effect by 4-6 weeks |
| Duration of Action | 6-12 weeks (sustained complement inhibition); dosing every 7-10 days for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) |
600 mg subcutaneous injection once weekly for 4 weeks, followed by 900 mg every 2 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR >=30 mL/min). Not studied in severe renal impairment (eGFR <30 mL/min) or ESRD. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C). |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established. |
| Geriatric use | No dose adjustment recommended based on age; but monitor for increased susceptibility to infections due to age-related immune decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ENJAYMO (ENJAYMO).
| Breastfeeding | It is not known whether ENJAYMO is excreted in human milk. Because many drugs are excreted in breast milk and the potential for adverse reactions in nursing infants exists, a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. The M/P ratio has not been established. |
| Teratogenic Risk | Based on its mechanism of action (C1 esterase inhibitor replacement), human pregnancy data are limited to case reports and registries. In animal studies, no teratogenic effects were observed at doses up to 15 times the human dose. However, because C1 inhibitor deficiency can itself increase pregnancy complications, the risk is likely primarily from uncontrolled disease. Per the manufacturer, ENJAYMO should be used during pregnancy only if clearly needed. No specific trimester risks are defined; careful risk-benefit assessment is required. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known hypersensitivity to sutimlimab-jome or any of its excipients.","Patients with unresolved serious infection, particularly those with systemic infections requiring treatment.","Patients not vaccinated against encapsulated bacteria as per guidelines (if vaccination can be given, delay treatment until at least 2 weeks after vaccination; if urgent, give prophylactic antibiotics)."]
| Precautions | ["Serious infections: ENJAYMO increases susceptibility to infections from encapsulated bacteria, particularly Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. Vaccination according to guidelines is required.","Infusion-related reactions: May occur. Monitor during infusion.","Thromboembolic events: Increased risk; monitor for signs."] |
| Food/Dietary | No known food interactions. Patients should avoid cold foods/drinks if they trigger hemolysis; otherwise no dietary restrictions. |
Loading safety data…
| Fetal Monitoring | During pregnancy, monitor for signs and symptoms of hereditary angioedema (HAE) attacks, as disease exacerbation may occur. In the absence of lactation data and potential risks, monitor the infant for adverse effects if breastfeeding is continued. No specific fetal monitoring is mandated, but standard prenatal care should be maintained with attention to pregnancy outcomes, including preterm birth or low birth weight, which have been reported in HAE patients. |
| Fertility Effects | No dedicated fertility studies in humans have been conducted with ENJAYMO. In animal studies, no effects on fertility or reproductive performance were observed at doses up to 15 times the human dose. Therefore, based on available data, ENJAYMO is not expected to impair fertility in males or females. |
| Clinical Pearls | ENJAYMO (sutimlimab) is a monoclonal antibody targeting complement component C1s, approved for hemolysis in cold agglutinin disease (CAD). Administer as IV infusion over 60 minutes. Premedicate with antihistamines and corticosteroids to reduce infusion reactions. Monitor for hemolytic episodes, especially after infections or cold exposure. Do not administer live vaccines during therapy. Monitor liver function tests due to potential transaminase elevations. Dose adjustment not required in renal impairment. |
| Patient Advice | ENJAYMO is given as an intravenous infusion every 2 weeks for 3 doses, then every 3 weeks. · You may experience infusion reactions such as fever, chills, headache, or nausea; tell your doctor immediately. · Avoid cold exposure as it can worsen your condition. · Do not receive live vaccines (e.g., MMR, yellow fever) during treatment. · Report any signs of infection, jaundice, or dark urine promptly. · Call your doctor if you have symptoms of liver problems: severe nausea, vomiting, abdominal pain, or yellowing of skin/eyes. |